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ABSTRACT
Objectives: An estimated 6%e10% of US adults took
a hypnotic drug for poor sleep in 2010. This study
extends previous reports associating hypnotics with
excess mortality.
Setting: A large integrated health system in the USA.
Design: Longitudinal electronic medical records were
extracted for a one-to-two matched cohort survival
analysis.
Subjects: Subjects (mean age 54years) were 10529
patients who received hypnotic prescriptions and
23676 matched controls with no hypnotic
prescriptions, followed for an average of 2.5years
between January 2002 and January 2007.
Main outcome measures: Data were adjusted for
age, gender, smoking, body mass index, ethnicity,
marital status, alcohol use and prior cancer. Hazard
ratios (HRs) for death were computed from Cox
proportional hazards models controlled for risk factors
and using up to 116 strata, which exactly matched
cases and controls by 12 classes of comorbidity.
Results: As predicted, patients prescribed any
hypnotic had substantially elevated hazards of dying
compared to those prescribed no hypnotics. For
groups prescribed 0.4e18, 18e132 and >132 doses/
year, HRs (95% CIs) were 3.60 (2.92 to 4.44), 4.43
(3.67 to 5.36) and 5.32 (4.50 to 6.30), respectively,
demonstrating a doseeresponse association. HRs
were elevated in separate analyses for several common
hypnotics, including zolpidem, temazepam,
eszopiclone, zaleplon, other benzodiazepines,
barbiturates and sedative antihistamines. Hypnotic use
in the upper third was associated with a signiﬁcant
elevation of incident cancer; HR¼1.35 (95% CI 1.18 to
1.55). Results were robust within groups suffering
each comorbidity, indicating that the death and cancer
hazards associated with hypnotic drugs were not
attributable to pre-existing disease.
Conclusions: Receiving hypnotic prescriptions was
associated with greater than threefold increased
hazards of death even when prescribed <18 pills/year.
This association held in separate analyses for several
commonly used hypnotics and for newer shorter-
acting drugs. Control of selective prescription of
hypnotics for patients in poor health did not explain the
observed excess mortality.
INTRODUCTION
Hypnotic drugs are among the most widely
used treatments in adult medicine. We
estimate that approximately 6%e10% of US
adults used these drugs in 2010, and the
percentages may be higher in parts of
Europe.
1 2 By 1979, the Cancer Prevention
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ARTICLE SUMMARY
Article focus
- Estimate the mortality risks associated with
speciﬁc currently popular hypnotics in
a matched cohort design, using proportional
hazards regression models.
- Estimate the cancer risks associated with speciﬁc
currently popular hypnotics.
- Explore what risk associated with hypnotics can
be attributed to confounders and comorbidity.
Key messages
- Patients receiving prescriptions for zolpidem,
temazepam and other hypnotics suffered over
four times the mortality as the matched hypnotic-
free control patients.
- Even patients prescribed fewer than 18 hypnotic
doses per year experienced increased mortality,
with greater mortality associated with greater
dosage prescribed.
- Among patients prescribed hypnotics, cancer
incidence was increased for several speciﬁc
types of cancer, with an overall cancer increase
of 35% among those prescribed high doses.
Strengths and limitations of this study
- Design strengths included matching patient and
control cohorts by age, gender and smoking.
Through stratiﬁed statistical analyses, patients
using hypnotics were matched with controls
diagnosed with the exactly the same combination
of 12 categories of comorbidity in up to 116 strata.
- The major limitation was that residual
confounding could not be fully excluded, due to
possible biases affecting which patients were
prescribed hypnotics and due to possible
imbalances in surveillance.
- Cohort studies demonstrating association do not
necessarily imply causality, but the preferable
randomised controlled trial method for assessing
hypnotic risks may be impractical due to ethical
and funding limitations.
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Open Access ResearchStudy I of the American Cancer Society had found that
both cigarette smoking and hypnotic consumption were
associated with excessive deaths,
34but the hypnotic
ﬁndings were discounted since the Cancer Prevention
Study I was not designed primarily to study these drugs.
At least 24 published studies have now examined
mortality associated with hypnotic consumption
(supplemental table 1). Of the 24 cited, 18 reported
signiﬁcant (p<0.05) associations of hypnotic usage with
increased mortality. Lack of uniformity of measured
elements makes it impossible to incorporate the majority
of these studies into a meta-analysis. Nevertheless, of 22
reports from which a risk or hazard ratio (HR) for
hypnotic-associated deaths could be estimated, 21
observed a risk exceeding 1.0 (p<0.001). One study
observed a RR of 1.0 associating total mortality with
hypnotics but found hypnotic use signiﬁcantly associated
with cancer mortality.
5 Three other studies have reported
an association of hypnotics with cancer deaths.
6e8 These
studies generally failed to report the speciﬁc hypnotic
drugs used by the participants, often confounded
hypnotics with tranquilisers not marketed for treatment
of insomnia, and usually omitted monitoring of the
quantities of hypnotic drugs provided participants during
the follow-up intervals. Moreover, previous studies had
insufﬁcient data on the short-acting benzodiazepine
agonists such as zolpidem, zaleplon, and eszopiclone that
now dominate the US market because their shorter
duration of action is believed to provide improved safety.
Using data from longitudinal electronic medical
records maintained by a large integrated US health
system, the authors planned a matched cohort study to
contrast mortality and cancer associations of zolpidem
and other new short-acting hypnotics with controls and
with older hypnotics.
METHODS
This study was conducted in the population served by the
Geisinger Health System (GHS), the largest rural inte-
grated health system in the USA. GHS serves a 41 county
area of Pennsylvania with approximately 2.5 million
people. The population is mostly of low socio-economic
status, having less than high school education and less
than one-third are insured under the Geisinger Health
Plan. During the study period, the Geisinger Clinic
provided primary care to approximately 250000 unique
outpatients annually, whose average duration of care in
the system exceeds 10 years. Geisinger implemented an
electronic health record (EHR) in 1996; it has been the
sole-source ambulatory record since 2001. All outpatient
encounters and related prescriptions are captured in the
EHR, and Geisinger’s implementation requires that both
these elements be linked to an ICD-9 diagnosis code.
Mortality ascertainment is updated monthly using the
Social Security Death Index, thought to be accurate, but
reliable cause-of-death data are not available.
Using a query into the EHR, we selected all 224757
primary care patients $18 years of age with outpatient
visits between 1 January 2002 and 30 September 2006.
A further query of this subset identiﬁed 12465 unique
patients who had at least one order for a hypnotic
medication and were followed-up and survived $3 months
subsequent to that order. For each hypnotic user, we
attempted to identify two controls with no record of
a hypnotic prescription in the EHR at any time from
among the 212292 remaining non-users. Non-user
controls were matched to the user cohort by: sex,
age 65 years, smoking status and start of period of
observation either by calendar date 61 year (preferred) or
by length of observation. A control likewise could not have
<3 months of observation in the EHR. We identiﬁed
24793 controls, there being fewer than 200 hypnotic users
for whom only one control could be matched. We
extracted demographic data, height and weight measure-
ments, diagnoses recorded in outpatient visit records,
problem lists and the cancer registry, and orders for all
medications, including the indication associated with that
order. Only hypnotics frequently prescribed in the EHR
and FDA-indicated by the US Food and Drug Adminis-
tration for insomnia were included in these analyses and
then only if it appeared that bedtime dosage was intended
(see supplemental ﬁles). Roughly three of four (76.3%) of
prescribed hypnotics had an explicitly sleep-related indi-
cation since physicians often use another diagnosis when
they believe that insomnia is secondary to other condi-
tions.
9 Medication orders were further reviewed by
a physician (DFK) to exclude initially identiﬁed patients
who did not fully meet criteria for users and matched non-
users of hypnotics. Two per cent of patients were excluded
for these reasons. Patients diagnosed with major cancer
(apart from non-melanoma skin cancers) before the
period of observation or within the ﬁrst 0.05 years of
follow-up were also excluded, reducing the numbers to
10531 users and 23674 matched non-user controls.
As prospectively planned, we examined the associa-
tions of hypnotic prescriptions with deaths, using Cox
proportional hazards models in SPSS V.12.0.0 (SPSS,
Inc.). Backwards stepwise models were calculated, with
likelihood ratio criteria of p<0.10 to retain a variable
and p<0.05 to re-enter. To control for potential
confounders, model covariates included age, sex,
ethnicity, marital status, body mass index (BMI) and self-
reported alcohol use and smoking status. To minimise
confounding by indication (eg, a physician might have
prescribed a hypnotic to treat a non-sleep condition
associated with disturbed sleep), comorbid diagnoses
were entered as strata in the primary models as
described in the following paragraph, and other models
were constructed limited to users and controls with
speciﬁc categories of comorbidity. To address the possi-
bility that hypnotics were prescribed for an emerging
condition that was not yet recorded as a diagnosis,
comorbid conditions were controlled whether ﬁrst
diagnosed before or during the period of observation.
To control for different classes of comorbidity and each
patient’s overall burden of comorbidities, the primary
2 Kripke DF, Langer RD, Kline LE. BMJ Open 2012;2:e000850. doi:10.1136/bmjopen-2012-000850proportional hazards models were constructed incorpo-
rating stratiﬁcation on up to 116 comorbidity combina-
tions. The 116 strata compared almost all hypnotic users
with non-users having exactly the same combinations of
12 classes of comorbidity. Two sets of additional models
were constructed for conﬁrmation of effects. One used
strata constructed using the numbers of comorbidities
comparing hazards in hypnotic users and non-users with
equivalent numbers of major comorbid conditions.
Another set of models restricted the population in each
model to users and controls having a speciﬁc class of
major chronic disease. Additional methods are described
in the online supplemental ﬁles.
This study followed the guidelines of the 2008 Decla-
ration of Helsinki and was approved and overseen by the
Geisinger Institutional Review Board (IRB). Secondary
approval was obtained from IRBs at the Scripps Clinic
and the University of California, San Diego. The data
were obtained under a data use agreement between the
lead authors (RDL and DFK) and the GHS. No person-
ally identifying data were included in the data distrib-
uted to the authors, the use of which the IRBs approved
without patient consent.
RESULTS
Zolpidem was the most frequently prescribed hypnotic
drug during the study interval from 2002 to 2006, and
temazepam was the next most common. Table 1
describes the characteristics of the study sample,
including details by categories of hypnotic used. The
hypnotic user and control cohorts were well matched in
age, gender, period of observation and BMI, and did not
Table 1 Characteristics of study participants
Non-users Any hypnotic users Zolpidem Temazepam
N 23674 10531 4338 2076
% Female* 62.7 63.9 64.8 60.0
Age (years, mean6SD)* 53.6 616.6 54.0616.9 54.0617.1 53.7617.2
Years of observation (mean6SD) 2.5061.43 2.4961.39 2.3461.33 2.5161.37
Comorbidity classes (mean 6SD)*** 1.0661.27 1.5361.55 1.4961.54 1.5361.52
Died during observation (% deceased)*** 295 (1.2) 638 (6.1) 265 (6.1) 143 (6.9)
BMI (%)***
<18.5 1.1 1.5 1.3 1.7
18.5e24.9 18.7 19.3 19.5 18.4
25e29.9 24.6 23.6 23.4 23.7
30e34.9 15.8 16.0 15.8 16.1
>35 13.1 14.4 13.7 14.2
Unknown 26.8 25.3 26.3 26.0
Marital status (%)***
Married 62.7 56.1 56.6 57.7
Divorced 7.9 12.0 11.4 11.9
Single 15.1 14.7 14.3 13.8
Separated 1.8 2.3 2.4 2.0
Widowed 12.5 14.8 15.3 14.4
Unknown 0.0 0.1 0.0 0.1
Ethnicity (%)***
White 93.5 97.0 97.2 96.8
Asian, Black, Hispanics 5.6 2.6 2.4 2.8
Native or other 0.9 0.4 0.4 0.3
Smoking status (%)***
Never 42.7 42.8 44.1 41.0
Unknown 3.1 3.2 3.6 3.5
Passive 0.7 0.5 0.5 0.3
Quit 32.6 29.9 29.3 30.6
Yes, now 21.0 23.5 22.5 24.5
Alcohol use (%)***
Yes 42.0 38.5 39.4 37.0
No 46.3 51.7 49.7 53.2
Unknown 11.7 9.7 10.9 9.8
Non-users: controls with no record of hypnotic prescription. Any hypnotic users: receiving any hypnotic prescription during the period of
observation. Zolpidem: users receiving prescriptions for zolpidem only. Temazepam: users receiving prescriptions for temazepam only. Years of
observation: the period of observation for users and non-users in years. Comorbidity classes: the number of disease classes diagnosed both
before and during the period of observation (see supplemental ﬁles for deﬁnitions of comorbidity classes). BMI (%): the percentage of the total
group within the BMI range deﬁned (kg/m
2). Ethnicity (%): the percentage in each self-reported ethnicity (Asians, Blacks and Hispanics were
combined because of small numbers). Alcohol use (%): a simple yes/no self-report. See supplemental table 3 for data concerning the less
commonly prescribed hypnotics. * indicates p<0.05 and *** indicates p<0.001, contrasting non-users versus all hypnotic users.
BMI, body mass index.
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status.
Table 2 presents the rates of comorbidities, including
incident diagnoses. These data indicated greater
comorbidity among hypnotic users for each class of
diagnoses, except for dementias. For most diagnoses,
there was greater comorbidity among hypnotic users
before the period of observation, and greater new
comorbidity incidence during the period of observation
(supplemental tables 4e6.)
Associations between hypnotic use and death
Associations between hypnotic prescriptions and deaths
from Cox proportional hazards models stratiﬁed by
comorbidity classes are presented in table 3. Patients
prescribed any hypnotic had substantially elevated
hazards of dying compared to those with equivalent
comorbidity who took no hypnotics. Importantly, the
death hazard was evident even in the lowest tertile of use.
Compared with non-users, patients prescribed 1e18 pills
of any hypnotic per year had a HR for death of 3.60
(95% CI 2.92 to 4.44). HRs increased further in the
second and third tertiles of estimated pills consumed at
4.43 (95% CI 3.67 to 5.36) and 5.32 (95% CI 4.50 to
6.30). For use of zolpidem, the HR in the lowest tertile
(5e130 mg/year) was similar, 3.93 (95% CI 2.98 to 5.17),
and not signiﬁcantly different from the HR for the
lowest tertile of temazepam, 3.71 (95% CI 2.55 to 5.38),
with exposure to 10e240 mg/year. For any hypnotic, or
for zolpidem or temazepam speciﬁcally, the hazards of
death in the middle tertiles of use were four to ﬁve times
higher in users compared to non-users, and the hazards
in the highest tertiles were ﬁve- or sixfold greater than
those in non-users, indicating doseeresponse relation-
ships for zolpidem and temazepam speciﬁcally and for
any hypnotic.
The death HR associated with prescriptions for less
commonly prescribed hypnotic drugs were likewise
elevated, and the conﬁdence limits of death hazards for
each other hypnotic overlapped that for zolpidem, with
the exception of eszopiclone, which was associated with
higher mortality (see supplemental ﬁles).
Figure 1 shows that the hazards of hypnotics were seen
in every age group. Whereas the absolute magnitude of
the added hazards associated with hypnotics increased
with age, as did the survival risks of hypnotic-free
controls, the ratio of death hazards of hypnotic users
compared to non-users was greater in users aged
18e55 years than in older groups (supplemental ﬁles).
Models addressing potential confounding of mortality
association by health status
To further address the possibility that hypnotic-associ-
ated hazards were due to use of hypnotic drugs by
patients with a greater burden of disease, so that elevated
risks of death might be attributable to comorbidities
rather than to hypnotic medications, we conducted
analyses within subgroups of hypnotic non-users and
users deﬁned by diagnoses in speciﬁc disease classes
(supplemental table 7). Allowing for differences in
sample size, hazards in subgroups restricted to patients
with speciﬁc diseases were generally consistent with the
overall ﬁndings. We also observed no statistically reliable
differences in death HR in subgroups constructed
to assess the overall burden of disease by stratifying on
the total number of comorbidities diagnosed for each
patient, and no reliable differences in death HR
comparing groups diagnosed with different numbers of
comorbidity classes. Whereas the raw death rate of the
user cohort was 4.86 times that of non-user controls
(table 1), adjustment for all covariates (eg, age, gender,
BMI, smoking) with stratiﬁcation by comorbidities only
reduced the overall HR to 4.56 (95% CI 3.95 to 5.26).
Associations between hypnotic use and incident major
cancer
Since prior studies suggested an association between
hypnotics and deaths from major cancers, we
Table 2 Comorbid diagnoses of non-users and users of hypnotics (percentages of total group)
Comorbidity Non-users Any hypnotic users Zolpidem Temazepam
Asthma*** 6.6 11.3 10.9 11.3
Cerebrovascular disease*** 3.8 6.2 5.9 6.1
Coronary heart disease*** 9.4 14.5 14.1 15.8
Chronic kidney disease*** 0.9 1.7 1.5 1.9
COPD*** 5.5 9.1 8.8 8.8
Cardiovascular disease, all*** 14.1 21.4 21.1 22.3
Dementia 0.6 0.6 0.7 0.2
Diabetes*** 14.6 17.9 17.8 18.5
Heart failure*** 3.2 6.6 6.6 6.6
Hypertension*** 37.5 42.8 41.9 43.9
Obesity*** 6.7 10.5 9.6 10.0
Reﬂux and peptic disease*** 15.0 27.9 26.9 26.3
Peripheral vascular disease*** 2.1 3.9 4.0 3.7
The percentages with each class of comorbidity diagnoses are shown for non-users and users of hypnotics. Among users, speciﬁc comorbidity
percentages are shown for those prescribed only zolpidem or only temazepam. Comorbidity classes are further deﬁned in supplemental table 2.
***Indicates p<0.001, contrasting non-users versus all hypnotic users.
4 Kripke DF, Langer RD, Kline LE. BMJ Open 2012;2:e000850. doi:10.1136/bmjopen-2012-000850constructed Cox models for major cancer incidence (ie,
excluding non-melanoma skin cancer incidence) and
excluding all patients who had major cancers diagnosed
before the period of observation. As shown in table 3,
there were modestly increased statistically signiﬁcant
cancer HRs for those prescribed any hypnotic compared
to non-users, with the middle and highest tertiles having
cancer HRs of 1.20 (95% CI 1.03 to 1.40) and 1.35 (95%
CI 1.18 to 1.55), respectively. The association with
zolpidem was signiﬁcant for the highest tertile. The HRs
for temazepam were signiﬁcant for the middle tertile
and the highest tertile. The cancer HR of 1.99 (95% CI
1.75 to 2.52) for the highest tertile of temazepam was
signiﬁcantly greater than the corresponding HRs for
zolpidem or for all hypnotics combined.
DISCUSSION
Patients with prescriptions for hypnotics had approxi-
mately 4.6 times the hazard of dying over an average
observation period of 2.5 years as compared to non-
users. These ﬁndings were robust with adjustment for
multiple potential confounders and consistent using
multiple strategies to address confounding by health
status. A doseeresponse effect was seen. Among users in
the highest tertiles of annualised dosages, the HRs for
death were 5.3, 5.7 and 6.6, respectively, for all hypnotics,
zolpidem alone and temazepam alone. This top third
of users were prescribed 92.8% of all the prescription
doses of hypnotics (supplemental ﬁgure 2). Those in the
top third were also 35% more likely to develop a new
major cancer.
Perhaps the most striking ﬁnding was that an
increased hazard for death was present even in the
lowest tertile of hypnotic use, such that hypnotic drugs
were associated with a 3.6-fold increased risk of dying for
patients using <18 hypnotic pills per year. Several strat-
egies to discover biases that could account for this
hazard, even at low levels of use, revealed none. None-
theless, some residual confounding is inevitable in our
results as a consequence of factors that were inade-
quately assessed. However, considering the minimal
impact of the major confounders for which we did
control upon the HRs, we think it unlikely that
confounding explains the high mortality that we found
associated with hypnotics.
Multiple causal pathways by which hypnotics might
lead to mortality have been demonstrated. Though the
acute lethality of benzodiazepine agonists seems less
than that of barbiturates, it has been demonstrated in
animals given high doses of benzodiazepine agonists,
especially in combination with alcohol. Moreover,
benzodiazepines and agonists are often present in
mixed-drug overdoses.
10 11 Compilation of randomised
controlled trials has shown that hypnotics increase inci-
dent depression.
12 Several non-randomised studies have
reported an increase in suicide associated with hypnotics
use,
81 3 e15 and depression may increase mortality
through other mechanisms besides suicide.
16 17
Controlled trials show that hypnotics impair motor
and cognitive skills, such as driving.
18 Hypnotics have
been associated with increased automobile crashes and
an increase in falls, due to hangover sedation.
19e22 In
some patients, hypnotics increase sleep apnoea, prolong
apnoeas or suppress respiratory drive, though among
other patients, there may be mild improvement.
23e25
Sleep apnoeas, in turn, may lead to motor vehicle
Table 3 HRs for deaths and for cancers with doseeresponse analyses
Hypnotic
Deaths Cancers
p Value HR (95% CI) p Value HR (95% CI)
Any hypnotic: doses/year <0.001 <0.001
No hypnotics, N¼23676 Reference Reference
0.4e18 pills/year, mean 8, N¼3491 <0.001 3.60 (2.92 to 4.44) 0.086 0.86 (0.72 to 1.02)
18e132 pills/year, mean 57, N¼3548 <0.001 4.43 (3.67 to 5.36) 0.022 1.20 (1.03 to 1.40)
>132 pills/year, mean 469, N¼3490 <0.001 5.32 (4.50 to 6.30) <0.001 1.35 (1.18 to 1.55)
Zolpidem only: mg/year <0.001 0.035
No zolpidem or other hypnotics, N¼23671 Reference Reference
Zolpidem 5e130 mg/year, mean 60, N¼1453 <0.001 3.93 (2.98 to 5.17) 0.095 0.79 (0.60 to 1.04)
Zolpidem 130e800 mg/year, mean 360, N¼1456 <0.001 4.54 (3.46 to 5.95) 0.585 1.07 (0.83 to 1.39)
Zolpidem >800 mg/year, mean 3600, N¼1427 <0.001 5.69 (4.58 to 7.07) 0.023 1.28 (1.03 to 1.59)
Temazepam only: mg/year <0.001 <0.001
NO temazepam or other hypnotics, N¼23674 Reference Reference
Temazepam 1e240 mg/year, mean 98, N¼798 <0.001 3.71 (2.55 to 5.38) 0.003 0.48 (0.30 to 0.77)
Temazepam 240e1640 mg/year, mean 683, N¼613 <0.001 4.15 (2.88 to 5.99) 0.024 1.44 (1.05 to 1.98)
Temazepam >1640 mg/year, mean 7777, N¼665 <0.001 6.56 (5.03 to 8.55) <0.001 1.99 (1.57 to 2.52)
HRs associated with levels of hypnotic consumption from Cox proportional hazards survival analyses, controlled for age, gender, ethnicity,
smoking status, body mass index, marital status and alcohol use and stratiﬁed by diagnoses in 12 classes of comorbidity. N: number of patients
in each dose group for deaths. Restrictions of stratiﬁcation produced small differences in N for the cancer analyses. p: probability that HR¼1
from Cox proportional hazards models. For each drug, the top p level is for the overall contrast among dosage categories (including the no
medication or reference category), and the lower p values are for the signiﬁcance of each HR referenced to no hypnotic use. HR: hazard ratio for
death or cancer (95% CI). Models for zolpidem and temazepam excluded patients receiving other hypnotics. See the supplemental ﬁles for
additional HRs.
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cardiovascular diseases and death.
26 Hypnotics may
cause somnambulistic night-eating syndromes resulting
in poor diet and obesity
27 as well as other automaton-like
behaviours, which can be dangerous.
28 29 Indeed, in
controlled trials, participants randomised to hypnotics
experience more adverse medical events overall than
those randomised to placebo.
21 30
Zolpidem has been shown to increase gastroesopha-
geal regurgitation.
31 In our sample, hypnotic prescrip-
tions were associated with increased diagnoses of
oesophageal regurgitation and peptic ulcer disease
(supplemental ﬁles). Increased regurgitation could
cause oesophageal damage and cancer. In randomised
controlled trials, patients receiving hypnotics reported
signiﬁcantly more infections.
32 Joya et al
32 inferred that
increased upper respiratory irritation and infection
might result from the increased gastroesophageal
regurgitation caused by hypnotics. Infections, in turn,
are major causes of mortality and cancer.
33
Sparse data from randomised controlled trials of
hypnotics suggested increased rates of cancer,
34 and
those ﬁndings are supported by studies demonstrating
carcinogenic effects of hypnotics in laboratory rodents
and by evidence that hypnotics can cause chromosomal
damage.
34 Our ﬁnding that for lymphomas, lung, colon
and prostate cancers, the HR for hypnotic usage was
even greater than the HR for current smoking (supple-
mental table 11) argues for speciﬁc biologic mecha-
nisms. It is possible that patients receiving hypnotics
experienced more medical care than non-users,
providing greater surveillance and potential cancer
detection as contrasted to non-users, even though the
Cox models matched users and non-users by numbers of
comorbidities. However, it would be hard to imagine
how greater surveillance of hypnotic users could explain
two- to threefold higher HR for some cancers with no
excess mortality for other cancers (see supplemental
table 11), whereas speciﬁc biological effects of hypnotics
would more plausibly explain the differences in HR
between cancers.
In addition to the residual confounding discussed
above, the data available for this study had further limi-
tations, which should be noted. Importantly, the EHR
provided information on medication orders but not
on dispensing. Accordingly, we were unable to verify that
the medications ordered were dispensed by a pharmacy,
and, if dispensed, whether the patient ingested the
prescribed hypnotic. Moreover, controls not receiving
hypnotic prescriptions might have taken hypnotics
prescribed for others or over-the-counter antihistamine
sleep drugs equivalent to prescribed antihistamines.
Such errors of overestimation of hypnotic consumption
among users or underestimation among controls would
lead to underestimation of the true hypnotic hazards.
We were unable to control for depression, anxiety and
other emotional factors because of Pennsylvania laws
protecting the conﬁdentiality of these diagnoses.
However, several previous studies reporting hypnotic
risks have controlled for these confounders.
7 35 Mallon
et al found that when depression, hypnotic use and other
risk factors were entered into a multivariate model for
all-cause mortality, hypnotic use was the strongest risk
factor among men (stronger than cigarette smoking). In
that analysis, depression was not an independent risk
factor for death in either men or women.
7 Moreover,
one might expect an emotional confounder to cause
insomnia, leading, in turn, to use of hypnotics, but
several large studies have reported that insomnia is not
a signiﬁcant mortality risk factor, especially when
hypnotic usage is controlled.
73 5 e37 Nevertheless, to the
extent that social and psychological problems lead
patients to receive hypnotics, and to the extent that
these problems cause death through pathways indepen-
dent of hypnotics, our ﬁndings might reﬂect some
confounding by those conditions.
CONCLUSIONS
Rough order-of-magnitude estimates at the end of the
supplemental ﬁles suggest that in 2010, hypnotics may
have been associated with 320000 to 507000 excess
deaths in the USA alone. From this non-randomised
study, we cannot be certain what portion of the mortality
associated with hypnotics may have been attributable to
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Figure 1 Survival curves for patients prescribed no hypnotic
are compared with survival curves for patients prescribed
hypnotics, divided into four age groups (age at commencement
of period of observation). These curves were derived from
a special Cox proportional hazards model in which those taking
and not taking hypnotics in the four age groups were coded as
eight categories of an independent predictor variable. The
curves represent the fraction of patients surviving over the
increasing years of observation until censored (died, lost to
follow-up or end of observation). Those censored <0.23 year
of observation were excluded. The red curves represent the
fact that a higher percentage of hypnotic users died during the
observation periods and fewer survived. Each curve was
adjusted for covariates except age (which shared excessive
colinearity with the age-based categories) and was adjusted for
comorbidity strata.
6 Kripke DF, Langer RD, Kline LE. BMJ Open 2012;2:e000850. doi:10.1136/bmjopen-2012-000850these drugs, but the consistency of our estimates across
a spectrum of health and disease suggests that the
mortality effect of hypnotics was substantial. Even 10000
yearly excess deaths caused by hypnotics would be too
many.
A randomised clinical trial of sufﬁcient duration and
size could provide deﬁnitive evidence for or against the
disturbing mortality hazards suggested by our study.
Some American NIH reviewers have opined that a rand-
omised trial of hypnotic lethality would be unethical. No
such trial has ever been mounted, perhaps for reasons
similar to the absence of randomised trials of cigarettes
and of skydiving without parachutes.
38 Absent rando-
mised trials of sufﬁcient dimensions, we must be guided
by observational data for hypnotics, as we have been
guided by similar data for cigarettes.
Excess mortality is associated with hypnotic use.
Hypnotic users had more prevalent disease of many sorts
than non-users before hypnotics were ordered. However,
the consistent results across varying levels of comorbidity
and the persistent elevated hazards within strata of users
and non-users matched for comorbid diagnoses strongly
suggest that neither the level of individual health nor
the presence of particular categories of comorbidity
explains the bulk of the hazard associated with the use of
hypnotic medications.
The meagre beneﬁts of hypnotics, as critically reviewed
by groups without ﬁnancial interest,
21 30 39 would not
justify substantial risks. A consensus is developing that
cognitive-behavioural therapy of chronic insomnia may
be more successful than hypnotics.
40 41 Against meagre
beneﬁts, it is prudent to weigh the evidence of mortality
risks from the current study and 24 previous reports, in
order to reconsider whether even short-term use of
hypnotics, as given qualiﬁed approval in National Insti-
tute for Clinical Excellence guidance,
39 is sufﬁciently safe.
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